



CERTIFICATE OF ANALYSIS




Product Details

Product name:	Anti-CD3 & DLL3 Reference Antibody (Tarlatamab)	Lot.No.:	P263257C
Target:	DLL3, CD3	Catalog:	CHBA072
Target Accession:	P07766 & Q9NYJ7	Concentration :	1 mg/mL
Clonality:	Bispecific	Isotype:	HLE-BiTE
Reactivity:	Human	Molecular Weight (kDa) :	105.2 kDa
Application:	Kinetics (SPR), ELISA, Bioactivity: FACS, Functional assay, Research in vivo	Endotoxin:	<1 EU/mg
Formulation:	Liquid: 100mM Pro-Ac, 20mM Arg pH 5.0 Lyophilization: 25mM histidine, 8% sucrose, 0.01% Tween80 pH6.2	Conjugation:	Unconjugated
Reconstitution:	For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.	Expression System:	CHO
Storage:	Upon receipt, store immediately at -20°C or lower for 24 months. Store aliquots at -80°C for up to 3 months. Avoid repeated freeze-thaw cycles.	Purification:	Protein A

Data


MASS



The detected molecular weight of Anti-CD3 & DLL3 Reference Antibody (Taratamab) is 91.84 kDa.


The antibody sequence matches the sequence in patent (WO2017021349). The Mass data suggested a smaller molecular weight of Tarlatamab (91.84 kDa) than the theoretical value (105.2 kDa, from the above patent). Functional assays demonstrated Tarlatamab retains the function of CD3 and DLL3.

Purity: SEC-HPLC




The purity of Anti-CD3 & DLL3 Reference Antibody (Taratamab) is 94.53%, determined by SEC-HPLC.

Purity: SDS-PAGE



Anti-CD3 & DLL3 Reference Antibody (Taratamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.


ELISA



Taratamab bound to DLL3 protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP), and read OD450. As shown in fig, Tarlatamab bound to huPD-1-his, and the EC50 was 0.010 nM


The products are for research use only. Not for use in diagnostic procedures.

Bioactivity: FACS




Tarlatamab bound to huCD3e-jurkat cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcy PE) , and test by flow cytometry. As shown in fig, Tarlatamab bound to huCD3e-jurkat cells, and the EC50 was 6.141 nM.

Bioactivity: FACS



Tarlatamab bound to hu-DLL3-HEK293 cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcy PE) , and test by flow cytometry. As shown in fig, Tarlatamab bound to hu-DLL3-HEK293 cells, and the EC50 was 0.337 nM.

Function: Luciferase



Co-incubation of Tarlatamab with Jurkat cells, then with the addition of hu-DLL3-HEK293 cells for 6 hours. Bright-Lite was used to detect the fluorescent signal.As shown in fig, Tarlatamab was able to activate the NF-AT signaling pathway, and the EC50 was 0.056 nM.

The products are for research use only. Not for use in diagnostic procedures.